WebMar 1, 2024 · In the CHAARTED trial, up-front docetaxel chemotherapy combined with ADT showed a significant survival benefit in the high-volume group (defined as having visceral metastases, or 4 or more bone metastases beyond the spine and pelvis), but not yet in the low-volume group. 9 Similarly, in the LATITUDE trial, there was a significant survival ... WebMedian OS was 55.5 months in patients who met the CHAARTED high criteria (vs 33.1 months in the trial). We evaluated 5 thresholds in the number of bone metastases (≥4, …
Prognostic Value of the LATITUDE and CHAARTED Risk …
WebMay 21, 2024 · a Of the patients with high-volume disease, 59% received concurrent docetaxel. b Of the patients with low-volume disease, 27% received concurrent docetaxel. Effect modification was tested by fitting the relevant factor-by-treatment interaction term in a Cox proportional hazard regression model along with the associated main effects terms. WebCT versus PSMA-PET stage, lesion number, and classification of LVD vs. HVD were determined by one blinded reader; PSMA-positive tumor volume (PSMA-TV) was quantified semi-automatically. Results: 85 CT-based CHAARTED-LVD and 20 CT-based CHAARTED-HVD patients were included. A PSMA-TV of ~40 ml was the optimal cutoff between CT … rabbi jonathan sacks vayechi
Revision of CHAARTED and LATITUDE criteria among
WebMar 1, 2024 · Forty-five patients (20.9%) were non-metastatic at CRPC. When classified using the risk stratification of the CHAARTED and LATITUDE studies, 110 patients … WebJun 9, 2014 · The CHAARTED trial enrolled 790 patients, diagnosed with hormone-sensitive metastatic prostate cancer between July 2006 and November 2012, who were known to … WebAug 7, 2024 · CHAARTED-defined risk/volume subgroups were balanced between the two treatment arms ( Table 1 ). In all, 428 (48%) patients were classified as having a low risk by the LATITUDE criteria and 402 (45%) using the CHAARTED criteria. High-risk disease using the LATITUDE and CHAARTED criteria was seen in 473 (52%) and 499 (55%) … rabbi jonathan cohen cleveland